Mainz Biomed NV

ColoAlert® now on DoctorBox: Mainz Biomed expands home‑testing reach, boosting colorectal cancer screening access across US, UK, Germany and beyond.

Mainz Biomed NV’s stock price experienced a 3% decline on the Frankfurt Stock Exchange, but the company’s recent clinical data on a pancreatic cancer screening test showed promising results with 100% sensitivity and 95% specificity.

Mainz Biomed NV has announced promising top-line results from a feasibility study on a non-invasive blood-based screening test for pancreatic cancer, achieving 100% sensitivity and 95% specificity in distinguishing cancer patients from healthy contr…